First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
A phase 1 study of OKI-219 reads out imminently.
After Genmab’s exit two more ADCs enter human trials.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
A new phase 3, Manifest-3, will start in April to support US filing.
The company takes a PD-L1 x VEGF asset into phase 3.
Intismeran autogene’s Interpath-001 trial reads out this year.
